MannKind plans to file novel inhaled insulin after Phase III success
This article was originally published in Scrip
Executive Summary
MannKind's two final pivotal Phase III studies of its novel rapid-acting inhaled insulin candidate, Afresa (Technosphere insulin), have met their primary endpoints in patients with types 1 and 2 diabetes.